



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Vedolizumab (anti- $\alpha 4\beta 7$ -integrin)

Cat. No.:	HY-P9911A
CAS No.:	943609-66-3
Target:	Integrin
Pathway:	Cytoskeleton
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Vedolizumab (anti- $\alpha 4\beta 7$ -integrin) is a humanized IgG1 monoclonal antibody that targets the $\alpha 4\beta 7$ integrin for the treatment of ulcerative colitis and Crohn's disease ^{[1][2]} .
In Vitro	Vedolizumab does not bind to the majority of memory CD4+ T lymphocytes (60%), neutrophils, and most monocytes. The highest level of vedolizumab binding is to a subset (25%) of human peripheral blood memory CD4+ T lymphocytes that include gut-homing interleukin 17 T-helper lymphocytes. Vedolizumab also binds to eosinophils at high levels, and to naive T-helper lymphocytes, naive and memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, and basophils at lower levels; vedolizumab binds to memory CD4+ T and B lymphocytes with subnanomolar potency ($EC_{50}=0.3-0.4$ nM). Vedolizumab selectively inhibits adhesion of $\alpha 4\beta 7$ -expressing cells to mucosal addressin cell adhesion molecule 1 ($IC_{50}=0.02-0.06$ $\mu\text{g}/\text{mL}$) and fibronectin ($IC_{50}=0.02$ $\mu\text{g}/\text{mL}$), but not vascular cell adhesion molecule 1 ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Blockade of $\alpha 4\beta 7$ receptors on T-lymphocytes has been shown to occur for several weeks after a single dose of vedolizumab. The drug concentration following the infusion has been shown to be dose related with a mean maximum concentration of 12.5 $\mu\text{g}/\text{mL}$ in those receiving 0.5 mg/kg of vedolizumab and 52.0 $\mu\text{g}/\text{mL}$ in those receiving 2 mg/kg. The serum half-life of these two doses is 9-12 days respectively and saturation of $\alpha 4\beta 7$ receptors on T-lymphocytes is >90% at both 4-6 weeks following infusion. In a dose ranging study, the serum drug concentrations increase with increasing dose and when regular induction infusions are used (on day 1, 15, 29 and 85), the serum half-life is between 15 and 22 days across all groups ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Soler D, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrintherapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75.
- [2]. Singh H, et al. Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med. 2016 Jan-Jun;7(1):4-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA